



## Berkshire West Area Prescribing Committee Policy Statement

<b>Drug Name</b>	Paliperidone palmitate prolonged-release suspension for injection (Trevicta®)
<b>Indication under review</b>	Patients with schizophrenia stabilised on monthly paliperidone injection (Xeplion®)
<b>Policy No:</b>	APC 139
<b>Date of Issue:</b>	January 2017
<b>Review Date:</b>	January 2020
<b>Policy Statement:</b> The Area Prescribing Committee recommends the prescribing of paliperidone palmitate 3 monthly intramuscular injection (Trevicta® 175mg, 263mg, 350mg, 525mg) for the treatment of schizophrenia.	
<b>Traffic Light Status</b>	<b>Amber</b>
<b>Key Points considered:</b> <ul style="list-style-type: none"><li>• Paliperidone palmitate is a dopamine D2 receptor and serotonin 5HT2 receptor antagonist, already in use as a monthly injection. Trevicta® will provide the longest dosing interval available for antipsychotic medication allowing patients to maintain an optimal level of treatment in their blood with fewer administrations when compared to currently available antipsychotic treatments.</li><li>• The prescribing of paliperidone 3 monthly injection must be on the initiation of a Consultant Psychiatrist in suitable patients who have been stable on monthly paliperidone palmitate monthly intramuscular injection (and stable for a minimum of 4 months)</li><li>• The APC noted that the reduced injection frequency may provide helpful support to patients by reducing injection frequency, which may free up time for other interventions to optimise mental and physical health outcomes</li></ul>	
<b>Date taken to APC:</b>	11 <sup>th</sup> January 2017
<b>Date Ratified by GPMOC on Behalf of the Board:</b>	18 <sup>th</sup> January 2017